Literature DB >> 35892008

Correction of Mitochondrial Dysfunction in the Complex Rehabilitation of COVID-19 Patients.

A E Tereshin1,2, V V Kiryanova1, D A Reshetnik2.   

Abstract

Objective. To study the efficacy of courses of i.v., Cytoflavin in combination with the standard rehabilitation program for postcovid syndrome for correction of postcovid asthenia. Materials and methods. Follow-up investigations were carried out in 45 patients with postcovid syndrome at the second stage of rehabilitation. Patients were divided into two groups of comparable sex and age. The volume of lung damage was also similar in both groups, at 25-80%. The 24 patients making up the comparison group received standard postcovid rehabilitation: pulsed magnetotherapy, inhalation therapy, aeroionotherapy, infrared laser therapy, courses of aerobic training, rational psychotherapy, and successive drug therapy. The 21 patients of the study group additionally received intravenous Cytoflavin daily for 10 days. The dynamics of increases in scores on the Rehabilitation Routing Scale, the Hamilton Depression Rating Scale (HDRS), the Asthenic Status Scale, and the 6-minute walk test at admission and discharge were also monitored. Results and conclusions. Addition of courses of intravenous Cytoflavin to the complex rehabilitation program for postcovid syndrome significantly improved the general functional state of the body, decreased levels of depression and asthenization, and increased physical exercise tolerance. © Springer Nature Switzerland AG 2022.

Entities:  

Keywords:  COVID-19; mitochondrial dysfunction; new coronavirus infection; postcovid asthenia; postcovid syndrome; rehabilitation

Year:  2022        PMID: 35892008      PMCID: PMC9304544          DOI: 10.1007/s11055-022-01269-5

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  12 in total

1.  Is mitochondrial bioenergetics and coenzyme Q10 the target of a virus causing COVID-19?

Authors:  A Gvozdjakova; F Klauco; J Kucharska; Z Sumbalova
Journal:  Bratisl Lek Listy       Date:  2020       Impact factor: 1.278

2.  The COVID-19 Effect on the Immune System and Mitochondrial Dynamics in Diabetes, Obesity, and Dementia.

Authors:  Katherine Holder; P Hemachandra Reddy
Journal:  Neuroscientist       Date:  2020-09-26       Impact factor: 7.519

3.  [Neuroprotective effect of cytoflavin in closed craniocerebral trauma].

Authors:  V V Bul'on; I V Zarubina; A L Kovalenko; L E Alekseeva; N S Sapronov
Journal:  Eksp Klin Farmakol       Date:  2003 Nov-Dec

Review 4.  Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: A possible approach to SARS-CoV-2 'long-haulers'?

Authors:  Emily Wood; Katherine H Hall; Warren Tate
Journal:  Chronic Dis Transl Med       Date:  2020-11-21

5.  Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce 'Brain Fog' and Results in Behavioral Changes that Favor Viral Survival.

Authors:  George B Stefano; Radek Ptacek; Hana Ptackova; Anders Martin; Richard M Kream
Journal:  Med Sci Monit       Date:  2021-01-25

Review 6.  Age-related mitochondrial dysfunction as a key factor in COVID-19 disease.

Authors:  Daniel J Moreno Fernández-Ayala; Plácido Navas; Guillermo López-Lluch
Journal:  Exp Gerontol       Date:  2020-11-07       Impact factor: 4.032

7.  Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19.

Authors:  Lichen Ouyang; Jie Gong
Journal:  Med Hypotheses       Date:  2020-08-05       Impact factor: 1.538

Review 8.  Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity.

Authors:  Johannes Burtscher; Giuseppe Cappellano; Akiko Omori; Takumi Koshiba; Grégoire P Millet
Journal:  iScience       Date:  2020-09-29

Review 9.  Coronavirus (Covid-19) sepsis: revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality.

Authors:  Santosh Shenoy
Journal:  Inflamm Res       Date:  2020-08-07       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.